Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05042232 · ClinicalTrials.gov registry record
A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19
A clinical trial of SARS-CoV-2 Acute Respiratory Disease, sponsored by Everly Health.
- Completed
- Registry status
- 239
- Enrollment target
- 1
- Study location
NCT05042232: Completed study of SARS-CoV-2 Acute Respiratory Disease, sponsored by Everly Health.
NCT05042232 is a study of SARS-CoV-2 Acute Respiratory Disease that has completed, run by Everly Health. The registered enrollment target is 239 participants, below the 567-participant average among 3 other SARS-CoV-2 Acute Respiratory Disease trials with a reported enrollment target (58% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05042232, a study of SARS-CoV-2 Acute Respiratory Disease, has completed, sponsored by Everly Health.
- COMPLETED
- Registry status
- 239 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to identify and describe patient behaviors and clinical outcomes among patients who have tested positive for mild to moderate COVID-19.
Conditions Studied
Interventions
- OTHER SARS-CoV-2 Positive
- OTHER SARS-CoV-2 Negative
Study Locations (1)
Texas
- Everlywell, Inc - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2021-04-19 |
| Est. Completion | 2022-06-14 |
What the finished NCT05042232 record still lists
NCT05042232 is an observational study that tracks outcomes without assigning an intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 567-participant average among 3 other SARS-CoV-2 Acute Respiratory Disease trials with a reported enrollment target (58% lower).
The record links to 1 condition, with SARS-CoV-2 Acute Respiratory Disease appearing as the primary indexed condition, and to 2 interventions - of which SARS-CoV-2 Positive is the first listed.
NCT05042232 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05042232 about?
NCT05042232 is a clinical study titled "A Prospective Virtual Study of Patient Reported Behaviors and Health Outcomes in Individuals With COVID-19". The primary objective of this study is to identify and describe patient behaviors and clinical outcomes among patients who have tested positive for mild to moderate COVID-19.
What is the current status of trial NCT05042232?
This trial is currently completed. The enrollment target is 239 participants. The study started on 2021-04-19. Estimated completion is 2022-06-14.
What conditions does trial NCT05042232 study?
This clinical trial studies the following conditions: SARS-CoV-2 Acute Respiratory Disease.
What interventions are being tested in trial NCT05042232?
The interventions under investigation include: SARS-CoV-2 Positive (OTHER), SARS-CoV-2 Negative (OTHER).
Who is sponsoring clinical trial NCT05042232?
This trial is sponsored by Everly Health, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05042232 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV-2 Acute Respiratory Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Clinical Care of Patients and Represent a Sustainable Approach Within a Federally Qualified Health Center?
ACTIVE NOT RECRUITING · NA
-
A Retrospective Study of COVID-19 Treatments
COMPLETED
-
Safety and Immunogenicity of RNA-based Vaccines Against SARS-CoV-2 Variants in Healthy Participants
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI